Program
lurbinectedin
Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.
Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.
Drug pagePM 01183: every studyMany companies study it; this page follows only the 27 they lead. All 53 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| PharmaMar | 202 open or running | phase 3since Apr 10, 2015 | Apr 6, 2009 | Aug 30, 2029phase 3 · NCT06088290 |
| Jazz Pharmaceuticalsits history only | 32 open or running | phase 2since Nov 8, 2021 | Nov 8, 2021 | Jan 28, 2028phase 2 · NCT05734066 |
| Luye Pharma Groupits history only | 21 open or running | phase 3since Jul 3, 2024 | Nov 5, 2020 | Dec 31, 2027phase 3 · NCT06496048 |
| Gilead Sciencesits history only | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Rocheits history only | 11 open or running | phase 3since Oct 12, 2021 | Oct 12, 2021 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of PharmaMar only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Apr 6, 2009.
- Mar 9, 2011Phase 1 study in LeukemiaNCT01314599 · 45 enrolled · United States
- Jul 26, 2011Phase 1 study in Major Advanced Solid Tumors Other Than ColorectalNCT01405391 · 42 enrolled · United States
- Jan 30, 2012Phase 2 study in Breast NeoplasmsNCT01525589 · 111 enrolled · United States, Spain
- Apr 2, 2013Phase 1 study in Breast NeoplasmsNCT01831089 · 69 enrolled · United States, Spain, Switzerland
- Sep 17, 2013Phase 2 study in Carcinoma, Non-Small-Cell LungNCT01951157 · 69 enrolled · United States
- Oct 22, 20133 phase 1 studiesNCT01980667, NCT01970553, NCT01970540
- Aug 5, 2014Phase 1 study in Breast NeoplasmsNCT02210364 · 81 enrolled · Belgium, Spain
- Apr 10, 2015Phase 3 study in Ovarian NeoplasmsNCT02421588 · 442 enrolled · United States
- May 6, 20152 phase 2 studiesNCT02454972, NCT02451007
- Sep 24, 2015Phase 3 study in Small Cell Lung CarcinomaNCT02566993 · 613 enrolled · United States, Argentina, Austria and more
- Nov 5, 2015Phase 2 study in GlioblastomaNCT02611024 · 316 enrolled · United States, France, Germany and more
- Sep 2, 20213 phase 1 studiesNCT05072106, NCT05063318, NCT05101265
- Nov 29, 2021Phase 3 study in Small Cell Lung CarcinomaNCT05153239 · 705 enrolled · United States, Australia, Austria and more
- Sep 28, 2023Phase 3 study in LeiomyosarcomaNCT06088290 · 469 enrolled · United States, Austria, Belgium and more
Ahead
- Aug 30, 2029Primary completion: phase 3 study in LeiomyosarcomaNCT06088290
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 PharmaMar leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06088290Leiomyosarcoma · United States, Austria, Belgium and more | 3 | Active, not recruiting | Aug 30, 2029 | 469 |
| NCT05153239Small Cell Lung Carcinoma · United States, Australia, Austria and more | 3 | Completed | Apr 10, 2026 | 705 |
| NCT05101265Advanced Solid Tumor · Spain | 1 | Recruiting | Jun 1, 2025 | 24 |
| NCT05072106Advanced Solid Tumor · Spain | 1 | Completed | Jan 18, 2022 | 11 |
| NCT05063318Advanced Solid Tumors · Spain | 1 | Completed | Apr 21, 2022 | 14 |
| NCT02611024Glioblastoma · United States, France, Germany and more | 2 | Completed | Jul 1, 2025 | 316 |
| NCT02566993Small Cell Lung Carcinoma · United States, Argentina, Austria and more | 3 | Completed | Feb 24, 2020 | 613 |
| NCT02451007Solid Tumors · United States, Spain | 2 | Completed | Aug 19, 2016 | 39 |
| NCT02454972Advanced Solid Tumors · United States, Belgium, France and more | 2 | Completed | Sep 18, 2020 | 345 |
| NCT02421588Ovarian Neoplasms · United States | 3 | Completed | Oct 12, 2018 | 442 |
| NCT02210364Breast Neoplasms · Belgium, Spain | 1 | Completed | Oct 2016 | 81 |
| NCT01980667Neoplasms · Switzerland, United Kingdom | 1 | Completed | Jan 5, 2017 | 41 |
| NCT01970553Neoplasms · Spain, United Kingdom | 1 | Completed | Oct 2013 | 47 |
| NCT01970540Neuroendocrine Tumors · Spain, United Kingdom | 1 | Completed | Aug 9, 2017 | 122 |
| NCT01951157Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Nov 2016 | 69 |
| NCT01831089Breast Neoplasms · United States, Spain, Switzerland | 1 | Completed | Jul 2016 | 69 |
| NCT01525589Breast Neoplasms · United States, Spain | 2 | Completed | Oct 2018 | 111 |
| NCT01405391Major Advanced Solid Tumors Other Than Colorectal · United States | 1 | Completed | Jan 2016 | 42 |
| NCT01314599Leukemia · United States | 1 | Completed | Jul 2015 | 45 |
| NCT00877474ADVANCED SOLID TUMORS · United States, Spain | 1 | Completed | Jun 2011 | 30 |
How it is read
Names in the registry
- “Lurbinectedin”, 13 entries
- “lurbinectedin (PM01183)”, 6 entries
- “Lurbinectedin (PM01183)”, 3 entries
- “PM01183”, 3 entries
- “Lurbinectedin (regions/countries where approved and available)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Breast Neoplasms, 3 studies
- Neoplasms, 2 studies
- Sarcoma, Ewing, 1 study
- Leiomyosarcoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.